These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17015675)

  • 1. Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy.
    Spitzer D; Wu X; Ma X; Xu L; Ponder KP; Atkinson JP
    J Immunol; 2006 Oct; 177(8):4953-6. PubMed ID: 17015675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD; Miwa T; Song WC
    J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane.
    Spitzer D; Unsinger J; Mao D; Wu X; Molina H; Atkinson JP
    J Immunol; 2005 Dec; 175(11):7763-70. PubMed ID: 16301687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury.
    Atkinson C; Qiao F; Yang X; Zhu P; Reaves N; Kulik L; Goddard M; Holers VM; Tomlinson S
    Circulation; 2015 Mar; 131(13):1171-80. PubMed ID: 25825397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure.
    Bao L; Wang Y; Chang A; Minto AW; Zhou J; Kang H; Haas M; Quigg RJ
    J Am Soc Nephrol; 2007 Mar; 18(3):811-22. PubMed ID: 17229915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor.
    Quigg RJ; Kozono Y; Berthiaume D; Lim A; Salant DJ; Weinfeld A; Griffin P; Kremmer E; Holers VM
    J Immunol; 1998 May; 160(9):4553-60. PubMed ID: 9574562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
    Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
    Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
    Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S
    J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody.
    Tang Y; Li Y; Qian G
    Chin Med J (Engl); 2002 Jul; 115(7):1064-9. PubMed ID: 12150744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
    Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
    Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y.
    Banda NK; Kraus DM; Muggli M; Bendele A; Holers VM; Arend WP
    J Immunol; 2003 Aug; 171(4):2109-15. PubMed ID: 12902517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure.
    Cunningham PN; Holers VM; Alexander JJ; Guthridge JM; Carroll MC; Quigg RJ
    Kidney Int; 2000 Oct; 58(4):1580-7. PubMed ID: 11012892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy.
    Korbelik M; Cecic I
    J Photochem Photobiol B; 2008 Oct; 93(1):53-9. PubMed ID: 18715798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice.
    Rehrig S; Fleming SD; Anderson J; Guthridge JM; Rakstang J; McQueen CE; Holers VM; Tsokos GC; Shea-Donohue T
    J Immunol; 2001 Nov; 167(10):5921-7. PubMed ID: 11698469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease.
    Costa GL; Benson JM; Seroogy CM; Achacoso P; Fathman CG; Nolan GP
    J Immunol; 2000 Apr; 164(7):3581-90. PubMed ID: 10725713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
    Miwa T; Zhou L; Tudoran R; Lambris JD; Madaio MP; Nangaku M; Molina H; Song WC
    Mol Immunol; 2007 Jan; 44(1-3):139-46. PubMed ID: 16887189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo.
    Ohta R; Kondor N; Dohi N; Tomlinson S; Imai M; Holers VM; Okada H; Okada N
    J Immunol; 2004 Jul; 173(1):205-13. PubMed ID: 15210776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing retroviral-mediated gene transfer into hepatocytes in vivo.
    Branchereau S; Calise D; Ferry N
    Hum Gene Ther; 1994 Jul; 5(7):803-8. PubMed ID: 7981306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors.
    Smiley WR; Laubert B; Howard BD; Ibañez C; Fong TC; Summers WS; Burrows FJ
    Hum Gene Ther; 1997 May; 8(8):965-77. PubMed ID: 9195219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
    Song H; Qiao F; Atkinson C; Holers VM; Tomlinson S
    J Immunol; 2007 Dec; 179(11):7860-7. PubMed ID: 18025232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.